Cooper Q1 revenue record $931.6M (+9% YoY); non-GAAP EPS $0.85 (+18%); FY24 guidance raised

COOPER COMPANIES, INC.

2024-Q1 EPS reported $0.41 revenue$931,600,000

Revenue of $931.6M, up 9% YoY; CooperVision $621.5M (+7%), CooperSurgical $310.1M (+12%).
GAAP EPS $0.41 (down 5% YoY); non-GAAP EPS $0.85 (up 18% YoY).
Gross margin improved to 67% (GAAP and non-GAAP) from 65%/66% last year.
FY2024 guidance raised: revenue $3,847-$3,897M, non-GAAP EPS $3.50-$3.58.
4-for-1 stock split effective Feb 20, 2024; free cash flow $4.6M; net debt $2.6B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COOPER COMPANIES, INC. reported its fiscal first quarter ended January 31, 2024 results: revenue $931.6 million, EPS $0.41. Guidance raised.

Period: its fiscal first quarter ended January 31, 2024
Revenue: $931.6 million
EPS: $0.41
Guidance: raised
Result: reported results

Exact text from the filing

COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2024. • Revenue increased 9% year-over-year to $931.6 million. CooperVision (CVI) revenue up 7% to $621.5 million, and CooperSurgical (CSI) revenue up 12% to $310.1 million. • GAAP diluted earnings per share (EPS) of $0.41, down $0.02 or 5%

View on SEC.gov

Browse all earnings releases →

COOPER COMPANIES, INC. filing history →

Source: SEC EDGAR

accession 0000711404-24-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.